Regeneron: Driven by Science

For over 25 years, Regeneron's vision has been to build an innovative company that consistently brings new medicines to patients with serious diseases.

Recent News

Regeneron and Teva Announce Global Collaboration to Develop and Commercialize Fasinumab, an Investigational NGF Antibody for Chronic Pain

09/20/16

TARRYTOWN, N.Y. and JERUSALEM, Sept. 20, 2016 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today a global1 agreement to develop and commercialize fasinumab, Regeneron's investigational NGF antibody in Phase 3 c...

Read more

Upcoming Events

BAML Global Healthcare Conference

09/14/16 at 6:25 AM ET

View Event

Morgan Stanley Global Healthcare Conference

09/12/16 at 11:40 AM ET

View Event




Close
Form content here please :)